Senti Bio to Present Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
November 04, 2021 09:02 ET
|
Senti Bio
- Preclinical data demonstrates functionality of SENTI-202 OR/NOT Logic Gated gene circuits for the elimination of AML cells while sparing healthy cells - - SENTI-202 is one of several pipeline...
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
October 21, 2021 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
September 13, 2021 07:00 ET
|
Adaptimmune Therapeutics plc
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients...
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
September 07, 2021 07:00 ET
|
Adaptimmune Therapeutics plc
- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the...
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
September 05, 2021 06:15 ET
|
Adaptimmune Therapeutics plc
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer...
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
May 26, 2021 08:00 ET
|
Senti Bio; BlueRock Therapeutics LP
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated...
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ISCT Annual Meeting
May 25, 2021 08:00 ET
|
Senti Bio
- Senti Bio has designed a scalable process for efficient manufacturing of allogeneic CAR-NK cell pipeline - - Large scale expansion of PBMC-NK cells and UCB-NK cells may provide a scalable source...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
May 19, 2021 17:00 ET
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
Senti Bio Announces Key Leadership Appointments
May 19, 2021 08:00 ET
|
Senti Bio
- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer - SOUTH SAN...
Adaptimmune Reports First Quarter Financial Results and Business Update
May 06, 2021 07:30 ET
|
Adaptimmune Therapeutics plc
- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in...